iTeos Therapeutics
ITOS
ITOS was delisted on the 28th of August, 2025.
153 hedge funds and large institutions have $489M invested in iTeos Therapeutics in 2023 Q1 according to their latest regulatory filings, with 25 funds opening new positions, 45 increasing their positions, 57 reducing their positions, and 17 closing their positions.
47% more first-time investments, than exits
New positions opened: 25 | Existing positions closed: 17
5% more funds holding
Funds holding: 146 → 153 (+7)
1.01% less ownership
Funds ownership: 101.74% → 100.73% (-1%)
21% less repeat investments, than reductions
Existing positions increased: 45 | Existing positions reduced: 57
31% less capital invested
Capital invested by funds: $704M → $489M (-$215M)
33% less funds holding in top 10
Funds holding in top 10: 3 → 2 (-1)
66% less call options, than puts
Call options by funds: $322K | Put options by funds: $948K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
6CM
683 Capital Management
New York
|
+$5.91M |
| 2 |
Dimensional Fund Advisors
Austin,
Texas
|
+$4.49M |
| 3 |
OCA
Octagon Capital Advisors
New York
|
+$2.71M |
| 4 |
SVCM
Saturn V Capital Management
Austin,
Texas
|
+$2.48M |
| 5 |
State Street
Boston,
Massachusetts
|
+$1.61M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$6.2M |
| 2 |
Bank of America
Charlotte,
North Carolina
|
-$5.64M |
| 3 |
Morgan Stanley
New York
|
-$5.08M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
-$2.55M |
| 5 |
AP
Advisors Preferred
Rockville,
Maryland
|
-$1.69M |
ITOS Hedge Fund Activity: Q1 2023 in Review
153 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in iTeos Therapeutics (ITOS) for Q1 2023, worth a combined $489M — down 31% from $704M a quarter earlier.
Buyers outnumbered sellers: 25 funds opened new ITOS positions and 17 closed out — a net gain of 8 holders — while 45 added to existing stakes and 57 trimmed.
The largest buyer was 683 Capital Management, adding an estimated $5.91M. The largest seller was Millennium Management, cutting an estimated $6.2M.
- 153 institutional investors held iTeos Therapeutics (ITOS) as of Q1 2023, up from 146 in Q4 2022.
- Funds reported $489M of iTeos Therapeutics stock for Q1 2023, down 31% quarter-over-quarter.
- 25 funds opened new iTeos Therapeutics positions in Q1 2023 and 17 closed out, a net change of +8 holders.
- The largest iTeos Therapeutics buyer in Q1 2023 was 683 Capital Management, an estimated $5.91M added.
- The largest iTeos Therapeutics seller in Q1 2023 was Millennium Management, an estimated $6.2M sold.
Based on aggregated 13F filings for Q1 2023.